Experience

•2018~ present, President, Development Center for Biotechnology (DCB)

•Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

•Chairman, Taiwan Bio Industry Organization

•Chairman, Taiwan Antibody Association

•Vice President, Precision Medicine & Molecular Diagnostics Industry Association of Taiwan​

•Director, Institute for Biotechnology and Medicine Industry(IBMI)

•Director, Taipei Biotechnology Service and Business Trade Association

•Director, Chinese Association for Industrial Technology Advancement

•Director, Taiwan Pharmaceutical Manufacture and Development Association

•Supervisor, Monte Jade Science and Technology Association of Taiwan

•2017~ 2018, Acting President, Development Center for Biotechnology (DCB)

•2017~ 2018, Vice President, Development Center for Biotechnology (DCB)

•2014~2017, Executive Director, Institute of Biologics, Development Center for Biotechnology (DCB)

•2013~2014, Director/Senior Research Fellow, Department of Protein Engineering, Development Center for Biotechnology (DCB)

•2008~2009, Founder/Chairman/CEO, Geniusway Biotech.

•2006~2008, Founder/Chairman/CEO, Geniusway Technology

•2000~2004, Cofounder/Chief Scientific Officer/Vice President of Business Development, AbGenomics Inc.

•1996~2000, Associate Professor, Institute of Molecular Medicine, College of Medicine, National Taiwan University

•1995~1996, Lecturer, Institute of Molecular Medicine, College of Medicine, National Taiwan University

•1992~1995, Jane-Coffin-Childs Memorial Fund Fellow, Department of Embryology, Carnegie Institution of Washington, Baltimore, Maryland, USA

Accomplishment

•Non-column glycohemoglobin A1C Test (1979)

•Non-extraction Testosterone RIA (1980)

•T3, T4, and TSH EIAs, microwell format (1984)

•Apolipoprotein A RIA (1985)

•Home pregnancy EIA (1985)

•Avian Infectious Diseases - 4 products (1985)

•Lyme disease EIA; for Canine (1986)

•Adenovirus & Enteric Adeno 40/41 EIAs (1987)

•HIV Latex Test (1987)

•Recombinant HIV EIA (1988)

•Clostridium difficile EIA (1990)

•E coli Toxin EIA (1995)

•Helicobacter pylori Stool Antigen EIA (1998)

•Helicobacter pylori Stool Antigen Rapid Test (2001)

•Enterovirus EIA/Rapid Test – prototype (2005/2011)

•COVID-19 Antigen Rapid Test (2020)

•Effectiveness of Cancer Treatment癌症個人化療效 (Precision Medicine)……

Dr. Chung-Yi Wu obtained his Ph.D. degree from the Department of Applied Chemistry at National Chiao Tung University. He joined Academician Chi-Huey Wong’s lab for his postdoctoral research.

In 2006, Dr. Wu accepted a position as an assistant research fellow at the Genomic Research Center in Academia Sinica to continue his research in glycoscience and obtained his position as research fellow in 2016. During this period, Dr. Wu published more than 100 academic papers and was granted for more than 40 patents. His achievements garnered him prestigious awards such as the 2014 American Chemical Society David Y. Gin New Investigator Award, Taiwan Bio-Development Foundation Lecturer Scholar Award, and National Chiao Tung University Applied Chemistry Department Distinguished Alumnus Award. Moreover, Dr. Wu is the main contributor of the more than 20 patents in the field of homogenous antibody, glycoprotein, glycovaccine, and glycoarray technologies that were transferred from Academia Sinica to our company.

Dr. Shugene Lynn is the Chief Executive Officer and a member of the Board of Directors of United BioPharma (UBP). She also serves as a board member of several companies within the UBI group. Prior to joining UBP in January 2019, she was the executive vice president of corporate development at UBI Asia, responsible for corporate strategic planning and financing

She has been with the UBI group since 1999, beginning as a bench scientist with increasing responsibility from project to program management, to corporate development, and has been associated with every step along the path of UBI growth in Asia. She was the first scientist in the UBI group to be engaged in the antibody humanization platform, and has since led a team to build the therapeutic monoclonal antibody process development platform, and brought the HIV drug candidate UB-421 from cell line development to clinical phase I and II stages. During her tenure at UBI Asia, the company was awarded 11 government research grants, and sponsored three monoclonal antibody drug candidates into clinical trials.

Dr. Lynn received her B.S. in plant pathology and Ph.D. in life sciences from the Institute of Zoology both from National Taiwan University. She completed her postdoctoral training at Academia Sinica and received the Outstanding Postdoctoral Fellow Award in 1998 for her eight first author publications in international journals.

Department of Quality Control (2001-2015)

─ Managed QC team and continuously improve its work efficiency

─ Kept the quality control in compliance with global standards

─ Helped to establish Quality Assurance system

─ Co-host customer GMP audits and authority inspections

Expertise

Audrey has rich experiences as a partner and leaders in PwC and sophisticated experience in assisting the development of biotech/med-tech industry/digital health industries. She is familiar with stakeholders in the biotech ecosystem and their demands in every stage including,

Project selection/ Business models / Deal structures / Exit strategies (cross border merger and acquisition and IPO). She successfully assists many biotech and med-tech companies to become publicly listed in Taiwan, the United States, and Hong Kong exchanges.